Background:

Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2].

Nefopam hydrochloride (Fenazoxine hydrochloride) is a non-opioid, non-steroidal, centrally acting analgesic drug that is derivative of the non-sedative benzoxazocine[1].Constitutively elevated β-catenin leads to a delayed and fibrous fracture repair process, and Nefopam inhibits β-catenin mediated signaling during skin wound repair3].

参考文献:
[1]. Kim KH, et al. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27(2):103-11.